Short Interest Buzzer: Accuray (NASDAQ:ARAY) Could Improve Your Long Portfolio After Less Shorts Reported

November 24, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Buzzer: Accuray (NASDAQ:ARAY) Could Improve Your Long Portfolio After Less Shorts Reported

The stock of Accuray (NASDAQ:ARAY) registered a decrease of 3.94% in short interest. ARAY’s total short interest was 7.85M shares in November as published by FINRA. Its down 3.94% from 8.17 million shares, reported previously. With 651,400 shares average volume, it will take short sellers 12 days to cover their ARAY’s short positions. The short interest to Accuray’s float is 10.58%. The stock increased 0.96% or $0.05 on November 23, hitting $5.25. About 264,658 shares traded hands. Accuray Incorporated (NASDAQ:ARAY) has declined 14.36% since April 22, 2016 and is downtrending. It has underperformed by 19.76% the S&P500.

Accuray Incorporated is a radiation oncology company. The company has a market cap of $420.80 million. The Firm develops, makes and markets medical devices used in radiation therapy for the treatment of cancer patients. It currently has negative earnings. The Company’s products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform.

Insitutional Activity: The institutional sentiment increased to 1.29 in 2016 Q2. Its up 0.17, from 1.12 in 2016Q1. The ratio improved, as 16 funds sold all Accuray Incorporated shares owned while 35 reduced positions. 17 funds bought stakes while 40 increased positions. They now own 71.42 million shares or 12.01% less from 81.17 million shares in 2016Q1.
D E Shaw & Communications owns 1.39M shares or 0.01% of their US portfolio. State Board Of Administration Of Florida Retirement Systems holds 71,909 shares or 0% of its portfolio. Lpl Ltd Liability Com holds 15,985 shares or 0% of its portfolio. Invesco Limited owns 30,736 shares or 0% of their US portfolio. Rk Capital Mgmt Limited has invested 0.61% of its portfolio in Accuray Incorporated (NASDAQ:ARAY). Lapides Asset Mngmt Limited Co accumulated 2.08% or 2.16M shares. Moreover, National Bank Of America De has 0% invested in Accuray Incorporated (NASDAQ:ARAY) for 193,792 shares. The California-based Menta Capital Ltd Liability Company has invested 0.18% in Accuray Incorporated (NASDAQ:ARAY). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Accuray Incorporated (NASDAQ:ARAY) for 1,427 shares. Sei Investments has 0% invested in the company for 10,729 shares. Cubist Systematic Strategies Ltd Limited Liability Company, a Connecticut-based fund reported 1,388 shares. Moreover, Partner Fund L P has 0.91% invested in Accuray Incorporated (NASDAQ:ARAY) for 5.78M shares. Cypress Capital Lc (Wy) accumulated 0% or 90 shares. Salient Advsrs Lc holds 0% or 10,000 shares in its portfolio. Metropolitan Life Insurance Ny, a New York-based fund reported 55,663 shares.

Accuray Incorporated (NASDAQ:ARAY) Ratings Coverage

Out of 3 analysts covering Accuray (NASDAQ:ARAY), 1 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 33% are positive. Accuray has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The company was initiated on Tuesday, September 13 by Cowen & Co. RBC Capital Markets initiated it with “Sector Perform” rating and $8 target price in Tuesday, December 22 report. On Friday, August 21 the stock rating was maintained by BTIG Research with “Neutral”. The company was upgraded on Wednesday, August 5 by Zacks. Citigroup initiated the shares of ARAY in a report on Thursday, November 12 with “Sell” rating. The firm has “Sector Perform” rating given on Friday, January 29 by RBC Capital Markets. The firm has “Buy” rating by Zacks given on Tuesday, August 25.

ARAY Company Profile

Accuray Incorporated, incorporated on February 22, 2001, is a radiation oncology company. The Firm develops, makes, sells and supports treatment solutions. It develops, makes and markets medical devices used in radiation therapy for the treatment of cancer patients. The Company’s suite of products includes the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. The Company’s technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver a range of treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

More news for Accuray Incorporated (NASDAQ:ARAY) were recently published by: Fool.com, which released: “Better Buy: Intuitive Surgical, Inc. vs. Accuray Incorporated” on February 10, 2016. Prnewswire.com‘s article titled: “Accuray to Unveil New Technology at the ASTRO 2016 Annual Meeting” and published on September 22, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>